Last updated on August 2018

A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma


Brief description of study

The purpose of this trial is to assess the efficacy and safety of E7777 (improved purity ONTAK) in patients with persistent and recurrent cutaneous T-cell lymphoma. A lead-in dose-finding part was used to determine dose level 9 microgram per kilogram (mcg/kg) E7777 that is being used to test efficacy and safety.

Detailed Study Description

This is a multicenter, open-label, single-arm study of E7777 in participants with recurrent or persistent Cutaneous T-Cell Lymphoma (CTCL). The study consists of an initial Lead-in part (to select recommended dose of E7777 for Main part), followed by the Main part (to test efficacy). Lead in part is complete and main study is ongoing. Participants will move through three phases while on study: Pretreatment Phase, Treatment Phase, and Extension Phase and a Follow-up Period.

Clinical Study Identifier: NCT01871727

Contact Investigators or Research Sites near you

Start Over

Eisai Medical Information

Stanford Cancer Institute
Stanford, CA United States
0.31miles
  Connect »